Exact Sciences Corporation maintained revenue guidance for the full year of 2024. For the period, the company has maintained its revenue guidance of $2.810 billion to $2.850 billion, assuming: screening revenue of $2.155 billion to $2.175 billion, and precision oncology revenue of $655 billion to $675 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.14 USD | -1.75% | -3.01% | -43.04% |
Jun. 11 | Exact Sciences Seeks Acquisitions | CI |
Jun. 11 | Transcript : Exact Sciences Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 03:20 PM |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.04% | 7.78B | |
+12.75% | 3.73B | |
-20.15% | 2.01B | |
-22.61% | 1.63B | |
+23.82% | 1.08B | |
+24.08% | 776M | |
-11.14% | 679M | |
-29.59% | 508M | |
-0.40% | 291M | |
-15.70% | 162M |
- Stock Market
- Equities
- EXAS Stock
- News Exact Sciences Corporation
- Exact Sciences Corporation Maintains Revenue Guidance for the Full Year of 2024